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Oral iron supplements also increase hepcidin production causing decreased fractional absorption of subsequent doses. Frequent blood donors often become iron deficient. Therefore, they were enrolled in a two-year study involving continued blood donations and randomization to receive no pill, placebo, 19, or 38 mg ferrous gluconate for 60 days. Total body iron (TBI) did not change for the subset of donors in the no pill and placebo groups who completed both enrollment and final visits (P 5 .21 and P 5 .28, respectively). However, repeated measures regression analysis on the complete dataset estimated a significant decrease in TBI of 52 mg/year for the placebo and no pill groups (P 5 .001). The effects of 19 and 38 mg iron supplementation on TBI were indistinguishable (P 5 .54). TBI increased by 229 mg after the initial 60 days of iron supplementation (P < .0001) and was maintained at this higher level with continued iron supplementation following each subsequent donation. The TBI increase was apportioned 51 mg to red cell iron (P < .0001) and 174 mg to storage iron (P < .0001). Changes in storage iron were negatively impacted by 57 mg due to concurrent antacid use (P 5 .04). These findings in blood donors suggest that much lower doses of iron than are currently used will be effective for clinical treatment of iron deficiency anemia.
| I N T R O D U C T I O N
Iron deficiency and iron deficiency anemia are common among regular blood donors [1] [2] [3] [4] due to a loss of 200 to 250 mg of iron with each whole blood donation. The standard approach for the clinical treatment of iron deficiency is to prescribe 100 to 200 mg of elemental iron daily divided into two or three doses. 5 However, many patients report gastrointestinal (GI) symptoms, such as bloating, nausea, vomiting, and constipation or diarrhea. 6 Oral iron also acutely increases hepcidin synthesis, which decreases the fraction of subsequent iron doses absorbed by the GI tract. 7, 8 This has led to the idea of intermittent (i.e.
every-other-day or weekly) dosing regimens for the treatment of iron deficiency. 9, 10 An additional consideration is the potential for suppression of oral iron absorption when gastric pH is altered by calcium-containing supplements 11, 12 or proton pump inhibitors. 13 Consequently, methods for treatment of iron deficiency may benefit from broadened consideration of how optimal iron absorption and diminished GI side effects can be harmonized. These are of increased importance to blood collecting agencies as they seek to operationalize strategies to mitigate the prevalence of iron deficiency in their donors. 
| Calculation of iron compartments
TBI was computed by adding estimates for RBC and storage iron compartments. RBC iron was calculated as the quotient of estimated blood volume (EBV), 16 venous hemoglobin concentration (Hgb), and hemoglobin iron content, 17 and adjusted by 0.91 to accommodate central pooling and trapped plasma. 18 Estimates for storage iron were calculated using the method by Cook, et al. 19 forgoing the subsequent modification to sTfR reported by Pfeiffer 20 because it was based on a relatively small study 21 and the modification increased variability in our parameter estimates. Plasma ferritin was increased 5% to account for differences between plasma and serum values (Assay Manual, ADVIA 
| Data analyses
Two analytic datasets were developed including one for the 273 participants for whom venous blood samples were available at both enrollment and final visits ("paired analysis") and another to quantify the effect of various predictors on TBI ("longitudinal analysis", Figure 1 ).
The longitudinal analyses included an intention-to-treat repeated measures regression model that analyzed all study visits regardless of whether or not the participant completed the study (n 5 555).
Repeated measures models were developed with compound symmetry covariance, as in Cable, et al. 22 Covariates included race, age, gender, weight, smoking status, pregnancy history, menstrual status, blood center, number of donations in the past two years, and time since last donation, as well as an indicator variable for antacid use. Ferritin and sTfR were log base 10 transformed to better satisfy linear regression normality assumptions. All statistical analyses were performed using SAS V9.3 (SAS Institute, Inc., Cary, NC).
| Model specification
STRIDE was designed to detect long term (i.e. two-year) effects of group assignment on TBI; not to evaluate a specific temporal effect of group assignment on TBI. A repeated measures ANOVA model with constant (intercept) and slope (temporal) effects for each group was deemed unduly complex. First, nonsupplemented participants could be expected to have no immediate change from baseline (i.e. no constant effect) since they essentially continued their pre-STRIDE enrollment donation behavior. Second, iron supplemented participants could be expected to have no decline over time (i.e. no slope effect), since they received additional iron supplementation after each subsequent donation. Thus, rather than a comparison of groups by the pair of constant and slope effects, the comparison of groups might be achieved by the two slope effects of the nonsupplemented groups and the two constant effects of the iron supplemented groups. Therefore, iron status in the nonsupplemented groups was modeled as a continual, gradual rate of decline parameterized as a rate of change per year.
In contrast, iron status in the two iron supplemented groups was modeled as a change in iron stores immediately after enrollment parameterized as change in mg from baseline with persistence through the two-year study. While other models were entertained, since STRIDE was not designed to differentiate among nuances of any temporal effect, other models were statistically indistinguishable from the model presented. and 38 mg iron groups were indistinguishable for RBC iron (P 5 .54), storage iron (P 5 .61), and TBI (P 5 .54).
| R E S U LTS

| Longitudinal analyses of iron status at all visits reveals equal effects of 19 and 38 mg iron
Longitudinal multivariable regression analysis of 555 enrolled subjects across 3,168 follow-up visits over two years was performed to examine changes in iron balance between groups in more detail than the paired analysis allowed. Biometric indicators were equivalent at enrollment across randomization groups (Table 2) . Declines in TBI were observed in the No Pills (43 mg/year, P 5 .03) and Placebo groups (68 mg/year, P 5 .004) (Table 3) , and, were indistinguishable between the two groups for RBC iron (16 mg/year, P 5 .78), storage iron (39 mg/year, P 5 .38), and TBI (52 mg/year, P 5 .42). Increases in TBI of 216 and 240 mg occurred in the 19 and 38 mg iron groups, respectively (P < .0001 for both). RBC iron (P 5 .95), storage iron (P 5 .36), and TBI (P 5 .54) were indistinguishable in the 19 and 38 mg iron groups and demonstrated immediate increases from enrollment of 51 mg for RBC iron (P < .0001), 174 mg for storage iron (P < .0001), and 229 mg for TBI (P < .0001).
| Regression quantifies effects of iron supplementation relative to iron loss and antacid use
Continued blood donation over the two-year study period maintained a state of iron deficiency among most subjects in the No Pills and Placebo groups. The longitudinal model included known covariates of iron status in blood donors including the time since last donation and the number of donations made in the two years prior to the current donation. 22 The time since last donation parameter was a significant contributor to iron status (P < .0001). It was inversely proportional to the magnitude of TBI deficit and its effect on iron status could be quantified (Table 3) 
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TBI; while delaying it from 8 to 13 weeks to over 26 weeks increased TBI by 236 mg. The number of donations in the previous two years was also a significant contributor to iron status (P 5.002). Subjects with 10 or more donations in the previous two years had a TBI deficit of 153 mg compared to subjects donating one to three times. Finally, the prevalence of antacid use was approximately 20% corresponding to a 30 mg deficit in RBC iron, a 57 mg deficit in storage iron, and an 88 mg deficit in TBI (Table 3 ). This effect was significant only for storage iron (P 5 .04).
| DISCUSSION
Iron balance was assessed in 555 iron deficient subjects over 3,168 encounters as they underwent continued iron loss during two years of frequent blood donation. In both paired and repeated measures analyses, subjects randomized to receive 19 or 38 mg of elemental iron had statistically equivalent increases in RBC iron, storage iron, and TBI.
These findings are similar to those of Rimon and colleagues, 23 who observed equivalent increases in hemoglobin and ferritin in a prospective, randomized study of elderly hospitalized patients with iron deficiency anemia receiving 15, 50, or 150 mg of daily elemental iron over a 60 day interval. Therefore, it appears that iron deficiency among frequent blood donors can be mitigated by use of just 19 mg elemental iron daily for 60 days following each donation, especially because pill compliance was equivalent across groups. 14, 15 More broadly, these data suggest that much lower doses of iron than are currently used will effectively treat clinical iron deficiency and iron deficiency anemia.
Current voluntary whole blood donation standards in the U.S.
require a minimum of eight weeks between donations. Results from the present analysis indicate that donation every eight weeks produces an average decrement of 236 mg in TBI when compared to donation at >26 weeks. This finding is consistent with several recent studies indicating that recovery of iron stores following a single whole blood donation requires more than 26 weeks in many donors. [24] [25] [26] Oral iron supplementation of frequent blood donors produced a large increase in storage iron associated with a more modest relative increase in RBC iron in the time between blood donations. The differential increase within the two iron compartments resulted in a shift in the proportion of TBI allocated to storage iron from 15% to 20%. This is likely a result of the hemoglobin screening during qualification for blood donation, which prevents donation by those with severe anemia, but not by those with severely depleted iron stores.
Since no differences in iron, hemoglobin status, or compliance between the 19 and 38 mg iron groups were identified, the combined amount of dietary and supplemental iron absorbed between blood donations was equivalent. Equal absorption in the two groups may have occurred because fractional iron absorption of the 19 mg dose is increased, producing the same net iron absorption as the 38 mg dose.
In a previous study where donors received 38 mg daily iron for six months following a single whole blood donation, approximately 75% of TBI recovered in the first four weeks after blood donation with an additional 9%-15% recovery between 4 and 8 weeks after donation. Therefore, an alternative possibility is that iron absorption was initially greater among individuals taking 38 mg iron, but total iron absorbed over the entire interval between donations was equivalent between 19
24
and 38 mg doses. STRIDE was not designed or powered to detect differences in iron absorption kinetics between donors taking 19 and 38 mg iron to differentiate these two possibilities.
The prevalence of antacid use in the prior 30 days in the United
States is nearly 8%. 27 One in five participants reported antacid use at some time during STRIDE. When antacid use was included as a binary term in the repeated measures model, there was a nonsignificant (P 5 .07) decline of 88 mg in TBI, comprised of a nonsignificant (P 5 .27) decline of 30 mg in RBC iron and a significant (P 5 .04) decline of 57 mg in storage iron. The observation that antacid use was associated with a decrease in storage iron suggests that absorbed iron is preferentially utilized for erythropoiesis. This finding is consistent with other studies [11] [12] [13] suggesting that use of antacids or proton pump 
